Clinical Trials
32 trialsNCT07559929 2026-05-29
A Study of DXC006 With Immune Checkpoint Inhibitors or Platinum for Small Cell Lung Cancer.
Hangzhou DAC Biotechnology Co., Ltd.
Phase 1/2 Not yet recruiting
NCT05173142 2026-05-15
A Phase Ib/II Clinical Study Evaluating HMPL-453 Tartrate as Monotherapy and in Combination With Chemotherapy or Toripalimab in Advanced Solid Tumors
Hutchmed
Phase 1/2 Completed
NCT04322006 2026-05-13
A Phase I/II Study of TJ004309 for Advanced Solid Tumor
TJ Biopharma Co., Ltd.
Phase 1/2 Completed
NCT06975293 2026-04-21
STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas
STORM Therapeutics LTD
Phase 1/2 Recruiting
NCT07508761 2026-04-02
IPG7236 Combined With Toripalimab in Participants With Advanced Solid Tumors
Nanjing Immunophage Biotech Co., Ltd
Phase 1/2 Not yet recruiting
NCT06953323 2026-03-27
A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors
Wigen Biomedicine Technology (Shanghai) Co., Ltd.
Phase 1/2 Recruiting
NCT07281976 2026-02-12
A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2 Recruiting
NCT07392736 2026-02-06
A Phase I/IIa Study of AL8326 Combined With Toripalimab in the Treatment of Advanced Solid Tumors.
Advenchen Laboratories, LLC
Phase 1/2 Recruiting
NCT05518045 2026-02-04
A Study of LM-108 as Monotherapy or in Combination With Antitumor Therapies in Subjects With Advanced Solid Tumors
LaNova Medicines Limited
Phase 1/2 Active not recruiting
NCT06771622 2026-02-04
Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors
FBD Biologics Limited
Phase 1/2 Active not recruiting
NCT04284488 2026-01-08
Dose-escalation Study of APG-1387 and Toripalimab in Solid Tumors
Ascentage Pharma Group Inc.
Phase 1/2 Terminated
NCT07258979 2025-12-02
A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2 Recruiting
NCT06682780 2025-09-25
A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours
LaNova Medicines Limited
Phase 1/2 Recruiting
NCT06868199 2025-09-12
A Study of LM-168 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours
LaNova Medicines Limited
Phase 1/2 Recruiting
NCT07169994 2025-09-12
A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2 Recruiting
NCT06088004 2025-08-22
Phase â… /â…¡ Clinical Study to Evaluate ABO2011 in Advanced Solid Tumors
Suzhou Abogen Biosciences Co., Ltd.
Phase 1/2 Recruiting
NCT06208410 2025-07-25
A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors
Risen (Suzhou) Pharma Tech Co., Ltd.
Phase 1/2 Recruiting
NCT05102006 2025-06-03
A Phase Ib/II Clinical Study of LBL-007 in Combination With Toripalimab in Treatment of Advanced Malignant Tumors
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2 Completed
NCT04914286 2025-05-14
A Study of GFH018 in Combination With Toripalimab in Patients With Advanced Solid Tumors
Genfleet Therapeutics (Shanghai) Inc.
Phase 1/2 Completed
NCT05830539 2025-05-02
IN10018 Combination Therapy in Previously-treated Locally Advanced or Metastatic Solid Tumor Patients
InxMed (Shanghai) Co., Ltd.
Phase 1/2 Completed
NCT04785196 2025-02-26
APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors
Ascentage Pharma Group Inc.
Phase 1/2 Recruiting
NCT05188664 2025-02-17
Study of LaNova Medicines(LM)-302 in Combination With Toripalimab in Patients With Advanced Solid Tumors
LaNova Medicines Limited
Phase 1/2 Completed
NCT06038396 2025-01-29
A Study of RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid Tumors
RemeGen Co., Ltd.
Phase 1/2 Recruiting
NCT05615974 2024-12-19
A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors
LaNova Medicines Limited
Phase 1/2 Recruiting
NCT06117566 2024-11-25
A Study of WX390 Combined With Toripalimab in Patients With Advanced Solid Tumors
Shanghai Jiatan Pharmatech Co., Ltd
Phase 1/2 Recruiting
NCT06410703 2024-10-31
CAN1012 Combined With PD-1 in Patients With Solid Tumors
Canwell Biotech Limited
Phase 1/2 Unknown
NCT06079112 2024-09-19
9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 1/2 Recruiting
NCT05955105 2024-05-21
A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies
Innolake Biopharm
Phase 1/2 Recruiting
NCT05723432 2023-04-27
KD6001 in Combination With Anti-PD-1 Antibody in Patients With Advanced Melanoma
Shanghai Kanda Biotechnology Co., Ltd.
Phase 1/2 Unknown
NCT04481009 2022-12-12
A Study to Evaluate YH003 in Combination With Toripalimab (Anti-PD-1 mAb) in Subjects With Advanced Solid Tumors
Eucure (Beijing) Biopharma Co., Ltd
Phase 1/2 Completed
NCT05165849 2022-05-20
A Study of GFS101A in Combination With Toripalimab in Patients With Advanced Solid Tumors
Genfleet Therapeutics (Shanghai) Inc.
Phase 1/2 Withdrawn
NCT05103917 2021-11-02
A Study to Assess the Safety, Tolerability and Antitumor Activity of X4P-001 in Combination With TNBC
Abbisko Therapeutics Co, Ltd
Phase 1/2 Unknown